Janux Therapeutics is a biopharmaceutical firm that develops cancer therapies using its patented TRACTr technology. Its lead TRACTr product candidates, which target specific cancer cell antigens, are in the preclinical or discovery stage. Janux is also working on a bispecific product called TRACIr to enhance the anti-tumor activity of T cells.